Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an update.
Lumos Diagnostics has outlined key upcoming investor events and capital-raising opportunities as it prepares to report its third-quarter FY26 results. The company, a specialist in rapid point-of-care diagnostics, plans to release its Q3 FY26 numbers on 20 April 2026 and will brief investors and analysts via an online webinar the following day.
The company also reminded eligible shareholders of its ongoing Share Purchase Plan, which mirrors the terms of a recent placement to sophisticated and institutional investors and includes one free attaching option for every two new shares subscribed. The SPP, supported by detailed online resources including the prospectus and timetable, is scheduled to close at 5 p.m. AEST on 24 April 2026, giving existing investors a near-term opportunity to increase their exposure ahead of the quarterly results update.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd is an Australia-based company specializing in rapid, point-of-care diagnostic test technology that supports healthcare professionals in accurately diagnosing and managing medical conditions. The company provides customized assay development and manufacturing services, proprietary digital reader platforms, and develops, manufactures, and commercializes its own Lumos-branded point-of-care tests targeting infectious and inflammatory diseases.
Average Trading Volume: 5,110,328
Technical Sentiment Signal: Hold
Current Market Cap: A$156.9M
See more data about LDX stock on TipRanks’ Stock Analysis page.